<DOC>
	<DOCNO>NCT01118065</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well everolimus work treat patient progressive recurrent , unresectable , metastatic thyroid cancer .</brief_summary>
	<brief_title>Everolimus Treating Patients With Progressive Recurrent , Unresectable , Metastatic Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy everolimus patient progressive recurrent , unresectable , metastatic differentiate thyroid carcinoma . Secondary - To determine maximum percentage tumor reduction patient . - To describe activity time event endpoint . - To assess toxicity . - To determine evolution serum thyroglobulin . - To perform explorative pharmacogenomic , pharmacokinetic , translational study . ( exploratory ) - To investigate efficacy everolimus patient progressive recurrent , unresectable metastatic disease undifferentiated ( anaplastic ) medullary thyroid cancer . OUTLINE : Patients receive oral everolimus daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis thyroid cancer meeting ≥ 1 follow criterion : Progressive recurrent disease Metastatic disease Unresectable disease Meeting follow thyroid cancer subtypes : Differentiated thyroid cancer ( i.e. , papillary , follicular , Hurthle cell disease ) radioiodine refractory Undifferentiated thyroid cancer ( i.e. , anaplastic disease ) Medullary thyroid cancer Must receive prior everolimus mTOR inhibitor therapy Patients history brain metastasis neurologically stable follow definitive radiation and/or surgery require corticosteroid allow PATIENT CHARACTERISTICS : Karnofsky performance score 70100 % ANC ≥ 1,500/mm^³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 5.6 mmol/L Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN know liver metastasis ) Serum creatinine ≤ 2 time ULN Negative pregnancy test No malignancy , except nonmelanoma skin cancer , carcinoma situ cervix , malignancy diagnose current evidence malignancy within past 2 year PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>stage III papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
</DOC>